ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered antibody discovery and development, announced the approval of its application to transfer its securities to the Nasdaq Capital Market. This transition grants the company an additional 180-day compliance period, until August 18, 2025, to meet the minimum bid price requirement of $1.00 per share. The transfer from the Nasdaq Global Market to the Nasdaq Capital Market will occur on February 21, 2025, allowing IPA to maintain its listing while pursuing strategic initiatives.

ImmunoPrecise Antibodies Ltd. specializes in AI-driven antibody discovery and development through its subsidiaries, offering end-to-end solutions for next-generation antibody therapeutics. The company uses systems biology, multi-omics modeling, and artificial intelligence to discover specialized, fully human therapeutic antibodies for challenging disease targets.

Key takeaways

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has been approved to transfer its securities to the Nasdaq Capital Market.
The transfer allows IPA an additional 180-day compliance period to meet the minimum bid price requirement of $1.00 per share.
The company's common stock will move from the Nasdaq Global Market to the Nasdaq Capital Market on February 21, 2025.
ImmunoPrecise Antibodies Ltd. specializes in AI-driven antibody discovery and development, offering end-to-end solutions for next-generation antibody therapeutics.

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

Key takeaways

Discussion (0)